Cargando…
Conazoles
This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264770/ https://www.ncbi.nlm.nih.gov/pubmed/20657432 http://dx.doi.org/10.3390/molecules15064129 |
_version_ | 1783375563671470080 |
---|---|
author | Heeres, Jan Meerpoel, Lieven Lewi, Paul |
author_facet | Heeres, Jan Meerpoel, Lieven Lewi, Paul |
author_sort | Heeres, Jan |
collection | PubMed |
description | This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly restricted to topical applications. The attractive in vitro antifungal spectrum was a starting point to design more potent and especially orally active antifungal agents such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole. The chemistry, in vitro and in vivo antifungal activity, pharmacology, and clinical applications of these marketed conazoles has been described. |
format | Online Article Text |
id | pubmed-6264770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62647702018-12-04 Conazoles Heeres, Jan Meerpoel, Lieven Lewi, Paul Molecules Review This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly restricted to topical applications. The attractive in vitro antifungal spectrum was a starting point to design more potent and especially orally active antifungal agents such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole. The chemistry, in vitro and in vivo antifungal activity, pharmacology, and clinical applications of these marketed conazoles has been described. MDPI 2010-06-09 /pmc/articles/PMC6264770/ /pubmed/20657432 http://dx.doi.org/10.3390/molecules15064129 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Heeres, Jan Meerpoel, Lieven Lewi, Paul Conazoles |
title | Conazoles |
title_full | Conazoles |
title_fullStr | Conazoles |
title_full_unstemmed | Conazoles |
title_short | Conazoles |
title_sort | conazoles |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264770/ https://www.ncbi.nlm.nih.gov/pubmed/20657432 http://dx.doi.org/10.3390/molecules15064129 |
work_keys_str_mv | AT heeresjan conazoles AT meerpoellieven conazoles AT lewipaul conazoles |